A Phase 2 interventional study of ALXN2050 in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 11 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
The study will evaluate the efficacy and safety of the oral Factor D (FD) inhibitor ALXN2050 (ACH-0145228) monotherapy in patients with PNH that are treatment naïve, or patients currently treated with eculizumab who still experience anemia and reticulocytosis, or patients currently treated with ALXN2040 (danicopan) as monotherapy. After signing consent, participants will have periodic visits through Week 12, at which time the primary endpoint and key secondary assessments will be analyzed. Participants will continue on treatment past 12 weeks into a long-term extension portion of the trial.
Experimental: Open-label ALXN2050 Monotherapy orally
Group 1: Patients with PNH who are treatment naïve
Group 2: Patients with PNH who have received complement component 5 (C5) inhibition with eculizumab for at least 6 months, who continue to experience anemia and reticulocytes above the upper limit of normal (ULN) who will switch to ALXN2050 monotherapy
Group 3: Patients with PNH receiving danicopan monotherapy in study ACH471-103 will switch to ALXN2050 monotherapy
After signing the informed consent form, participants will enter the screening period. During the Screening Period, eligibility and screening assessments will be performed. Screening assessments may be spread over more than one visit if necessary. At the baseline visit, screened participants who continue to meet eligibility criteria will enter the Treatment Period.
The treatment phase will be followed by a long-term extension phase, where ALXN2050 will continue to be administered.
Blood will be collected to assess the efficacy endpoints, such as, change in hemoglobin (Hgb), lactate dehydrogenase (LDH), and other measures of hemolysis. Safety and transfusion requirements will also be assessed.
Participants will continue on treatment past 12 weeks in a long-term extension portion of the trial.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
This study's enrollment of 29 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Browse Hemoglobinuria, Paroxysmal studies →Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Eligibility Criteria:
Eligibility Criteria Specific for Group 1:
Eligibility Criteria Specific for Group 2:
Eligibility Criteria Specific for Group 3:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental: Open-label ALXN2050 Monotherapy ALXN2050 orally administered Group 1: Patients with PNH who are treatment naïve Group 2: Patient with PNH who have received complement component 5 (C5) inhibition with eculizumab for at least 6 months, who continue to experience anemia and reticulocytes above the upper limit of normal (ULN) Group 3: Patients with PNH who have received danicopan monotherapy during study ACH471-103
Drug: ALXN2050
Oral FD inhibitor
Also known as: ACH-0145228
Change From Baseline in Hgb at Week 12
Hgb baseline was defined as the lowest Hgb value observed between and including screening and first dose date. To address the impact of transfusion, Hgb values collected within 4 weeks after transfusion were not included in the primary efficacy analysis. Change from Baseline = Hgb at Week 12 - Baseline Hgb.
Time frame: Baseline, Week 12
Number of Participants Who Had Transfusion Avoidance During 12 Weeks of Treatment With ALXN2050
Transfusion avoidance: participants remained transfusion-free and did not require a transfusion during the period of interest.
Time frame: Baseline up to Week 12
Number of Red Blood Cell (RBC) Units Transfused During 12 Weeks of Treatment
Time frame: Baseline up to Week 12
Number of Transfusion Instances During 12 Weeks of Treatment
Time frame: Baseline up to Week 12
Change From Baseline in Lactate Dehydrogenase (LDH) at Week 12
Change from Baseline = Serum LDH levels at Week 12 - Baseline Serum LDH levels.
Time frame: Baseline, Week 12
Change From Baseline in Absolute Reticulocyte Count at Week 12
Change from Baseline = absolute reticulocyte count at Week 12 - Baseline reticulocyte count.
Time frame: Baseline, Week 12
Change From Baseline in Direct and Total Bilirubin at Week 12
Time frame: Baseline, Week 12
Change From Baseline in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Clone Size at Week 12
The PNH RBC clone size refers to the percentage of PNH-affected cells versus normal cells within the total cell population. Change from Baseline = PNH clone size at Week 12 - Baseline PNH clone size.
Time frame: Baseline, Week 12
Change From Baseline in Component 3 (C3) Fragment Deposition on PNH RBCs at Week 12
C3 fragment deposition on PNH RBC was used as a marker of intra and extravascular hemolysis. Data are presented for the change from baseline to Week 12 in percentage of PNH RBCs with C3 fragment deposition.
Time frame: Baseline, Week 12
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Events Leading to Discontinuation of Study Medication
An adverse event (AE) was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), or an important medical event or reaction. A TEAE was defined as an AE that emerged during treatment, had been absent prior to treatment, or worsened relative to the pretreatment state. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: From first dose of study drug up to Week 217
Change From Baseline in Hgb at the End of Treatment (EOT) During the LTE Period
Hgb baseline was defined as the lowest Hgb value observed between and including screening and first dose date. Change from Baseline = Hgb at the EOT visit - Baseline Hgb.
Time frame: Baseline, EOT visit (Maximum exposure: 213.4 weeks)
Change From Baseline in LDH at the EOT During the LTE Period
Change from Baseline = Serum LDH levels at the EOT visit - Baseline Serum LDH levels.
Time frame: Baseline, EOT visit (Maximum exposure: 213.4 weeks)
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale (Version 4) Total Score at Week 12
The FACIT-Fatigue scale is a collection of quality-of-life questionnaires pertaining to the management of fatigue symptoms due to chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores ranged from 0 to 52, with higher score indicating better quality of life.
Time frame: Baseline, Week 12
Change From Baseline in FACIT-Fatigue Scale (Version 4) Total Score at the EOT During the LTE Period
The FACIT-Fatigue scale is a collection of quality-of-life questionnaires pertaining to the management of fatigue symptoms due to chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores ranged from 0 to 52, with higher score indicating better quality of life.
Time frame: Baseline, EOT visit (Maximum exposure: 213.4 weeks)
| Milestone | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Started | 12 | 11 | 6 |
| Received at least 1 dose of study drug | 12 | 11 | 6 |
| Completed | 12 | 11 | 6 |
| Not completed | 0 | 0 | 0 |
| Milestone | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Started | 12 | 11 | 6 |
| Received at least 1 dose of study drug | 12 | 11 | 6 |
| Completed | 0 | 0 | 1 |
| Not completed | 12 | 11 | 5 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Study termination | 11 | 11 | 5 |
Hgb baseline was defined as the lowest Hgb value observed between and including screening and first dose date. To address the impact of transfusion, Hgb values collected within 4 weeks after transfusion were not included in the primary efficacy analysis. Change from Baseline = Hgb at Week 12 - Baseline Hgb.
| grams/liter | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Change From Baseline in Hgb at Week 12 | 35.6 ± 14.70 | 32.5 ± 20.03 | -3.7 ± 15.77 |
Transfusion avoidance: participants remained transfusion-free and did not require a transfusion during the period of interest.
| Participants | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Number of Participants Who Had Transfusion Avoidance During 12 Weeks of Treatment With ALXN2050 | 9 | 10 | 5 |
| RBC units | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Number of Red Blood Cell (RBC) Units Transfused During 12 Weeks of Treatment | 0.6 ± 1.24 | 0.1 ± 0.30 | 0.8 ± 2.04 |
| transfusion instances | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Number of Transfusion Instances During 12 Weeks of Treatment | 0.4 ± 0.90 | 0.1 ± 0.30 | 0.5 ± 1.22 |
Change from Baseline = Serum LDH levels at Week 12 - Baseline Serum LDH levels.
| units/liter | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Change From Baseline in Lactate Dehydrogenase (LDH) at Week 12 | -1310.8 ± 424.89 | 160.2 ± 279.57 | 88.7 ± 265.00 |
Change from Baseline = absolute reticulocyte count at Week 12 - Baseline reticulocyte count.
| 10^3 cells/microliter (μL) | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Change From Baseline in Absolute Reticulocyte Count at Week 12 | -100.6 ± 72.18 | -179.0 ± 117.30 | -24.0 ± 22.10 |
| micromoles (μmol)/liter | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Direct Bilirubin | -2.1 ± 2.10 | -6.3 ± 5.16 | 0.4 ± 0.89 |
| Total Bilirubin | -12.9 ± 10.07 | -23.3 ± 24.89 | 1.5 ± 2.81 |
The PNH RBC clone size refers to the percentage of PNH-affected cells versus normal cells within the total cell population. Change from Baseline = PNH clone size at Week 12 - Baseline PNH clone size.
| percentage of the total cell population | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Change From Baseline in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Clone Size at Week 12 | 41.9 ± 13.68 | 27.5 ± 21.60 | -12.0 ± 26.94 |
C3 fragment deposition on PNH RBC was used as a marker of intra and extravascular hemolysis. Data are presented for the change from baseline to Week 12 in percentage of PNH RBCs with C3 fragment deposition.
| percentage of PNH RBC | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Change From Baseline in Component 3 (C3) Fragment Deposition on PNH RBCs at Week 12 | 0.0 ± 0.00 | -388.6 ± 590.08 | 0.3 ± 0.35 |
An adverse event (AE) was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), or an important medical event or reaction. A TEAE was defined as an AE that emerged during treatment, had been absent prior to treatment, or worsened relative to the pretreatment state. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Any AEs | 12 | 10 | 6 |
| SAEs | 7 | 5 | 2 |
| AEs Leading to Discontinuation of Study Medication | 1 | 1 | 0 |
Hgb baseline was defined as the lowest Hgb value observed between and including screening and first dose date. Change from Baseline = Hgb at the EOT visit - Baseline Hgb.
| grams/liter | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Change From Baseline in Hgb at the End of Treatment (EOT) During the LTE Period | 44.9 ± 21.07 | 32.5 ± 7.17 | 2.4 ± 19.44 |
Change from Baseline = Serum LDH levels at the EOT visit - Baseline Serum LDH levels.
| units/liter | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Change From Baseline in LDH at the EOT During the LTE Period | -1084.1 ± 738.26 | 95.7 ± 223.88 | -61.4 ± 62.85 |
The FACIT-Fatigue scale is a collection of quality-of-life questionnaires pertaining to the management of fatigue symptoms due to chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores ranged from 0 to 52, with higher score indicating better quality of life.
| units on a scale | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale (Version 4) Total Score at Week 12 | 11.2 ± 13.20 | 5.1 ± 8.47 | 0.2 ± 3.13 |
The FACIT-Fatigue scale is a collection of quality-of-life questionnaires pertaining to the management of fatigue symptoms due to chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores ranged from 0 to 52, with higher score indicating better quality of life.
| units on a scale | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Change From Baseline in FACIT-Fatigue Scale (Version 4) Total Score at the EOT During the LTE Period | 12.6 ± 12.51 | 4.4 ± 7.26 | -3.4 ± 10.26 |
Collected over From first dose of study drug up to Week 217. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Treatment Naive | 0/12 (0%) | 7/12 (58.3%) | 12/12 (100%) |
| Group 2: Eculizumab Switch | 0/11 (0%) | 5/11 (45.5%) | 10/11 (90.9%) |
| Group 3: Danicopan Rollover | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| Breakthrough haemolysisBlood and lymphatic system disorders | 4/12 | 2/11 | 1/6 |
| Acute kidney injuryRenal and urinary disorders | 3/12 | 1/11 | 0/6 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/12 | 0/11 | 0/6 |
| ContusionInjury, poisoning and procedural complications | 0/12 | 0/11 | 1/6 |
| GastroenteritisInfections and infestations | 0/12 | 1/11 | 0/6 |
| Anaphylactic reactionImmune system disorders | 0/12 | 1/11 | 0/6 |
| COVID-19Infections and infestations | 0/12 | 1/11 | 0/6 |
| Intravascular haemolysisBlood and lymphatic system disorders | 0/12 | 1/11 | 0/6 |
| Campylobacter gastroenteritisInfections and infestations | 1/12 | 0/11 | 0/6 |
| HaemoglobinuriaRenal and urinary disorders | 1/12 | 0/11 | 0/6 |
| Event | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover |
|---|---|---|---|
| FatigueGeneral disorders | 6/12 | 1/11 | 3/6 |
| HeadacheNervous system disorders | 6/12 | 3/11 | 1/6 |
| COVID-19Infections and infestations | 4/12 | 2/11 | 3/6 |
| Upper respiratory tract infectionInfections and infestations | 6/12 | 1/11 | 2/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/12 | 4/11 | 1/6 |
| HaemolysisBlood and lymphatic system disorders | 0/12 | 4/11 | 0/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/12 | 4/11 | 2/6 |
| HaematuriaRenal and urinary disorders | 3/12 | 4/11 | 2/6 |
| NauseaGastrointestinal disorders | 4/12 | 2/11 | 1/6 |
| VomitingGastrointestinal disorders | 4/12 | 2/11 | 0/6 |
Full analysis set included all participants who received at least 1 dose of ALXN2050 in this study.
| Age, Continuous(years) | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover | Total |
|---|---|---|---|---|
| Mean | 43.75 ± 17.099 | 42.45 ± 13.419 | 40.50 ± 16.718 | 42.59 ± 15.186 |
| Sex: Female, Male(Participants) | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover | Total |
|---|---|---|---|---|
| Female | 4 | 7 | 3 | 14 |
| Male | 8 | 4 | 3 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 12 | 10 | 6 | 28 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 8 | 1 | 0 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 3 | 10 | 6 | 19 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| HgB(grams/liter) | Group 1: Treatment Naive | Group 2: Eculizumab Switch | Group 3: Danicopan Rollover | Total |
|---|---|---|---|---|
| Mean | 81.17 ± 11.731 | 91.00 ± 9.602 | 130.67 ± 19.180 | 95.14 ± 22.662 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vemircopan
Alexion Pharmaceuticals, Inc. →